The Evolution of Acquired Resistance to BRAF(V600E) kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. Xu G, Luo Y, Wu W, Liu X, et al. J Invest Dermatol 2022;142:445-458.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu G, Luo Y, Wu W, Liu X, et al. The Evolution of Acquired Resistance to BRAF(V600E) kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. J Invest Dermatol 2022;142:445-458.
PMID: 34358527